OptimizeRx Corp (OPRX) FinancialsOPRXOptimizeRx Corp

Evaluating the bottom line, OptimizeRx Corporation maintains a gross margin of 71.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -0.43%, while the net margin is -3.43%. These profitability ratios, combined with a Return on Equity (ROE) of 3.68%, provide a clear picture of how effectively OPRX converts its operational activities into shareholder value.

In the context of the broader market, OPRX competes directly with industry leaders such as ATGL and GDEV. With a market capitalization of $163.34M, it holds a leading position in the sector. When comparing efficiency, OPRX's gross margin of 71.32% stands against ATGL's 66.90% and GDEV's 65.43%. Such benchmarking helps identify whether OptimizeRx Corporation is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin improvement, reaching 71.32% in Q2 2026, which is a positive indicator of operational efficiency. Despite recent revenue challenges, the reaffirmed full-year revenue guidance of $95 million to $100 million reflects management's confidence in future performance.